A model for developing a decision support system to simulate national drug policy indicators

Archives of Medical Science

Volumn 7, Issue 5, 2011, Pages 744-746

  Abdollahiasl, Akbar ^a   Nikfar, Shekoufeh ^a,b,c   Kebriaeezadeh, Abbas ^a,c   Dinarvand, Rasoul ^a,c   Abdollahi, Mohammad ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL NEURAL NETWORK; DECISION MAKING; DECISION SUPPORT SYSTEM; DRUG CONTROL; DRUG MARKETING; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH CARE ACCESS; HEALTH CARE POLICY; MATHEMATICAL MODEL; NATIONAL DRUG POLICY; POPULATION DYNAMICS; QUESTIONNAIRE; STATISTICAL MODEL;

EID: 81555222777     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.25546     Document Type: Editorial

References (15)

1. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of national drug policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights 2005; 5: 5.
2. Abdollahiasl A, Nikfar S, Abdollahi M. Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: time for innovations and changes in policies and actions. Arch Med Sci 2011; 7: 365-7.
3. Nikfar S, Khatibi M, Abdollahi-Asl A, Abdollahi M. Cost and utilization study of antidotes: an Iranian experience. Int J Pharmacol 2011; 7: 46-9.
4. Abdollahiasl A, Kebriaeezadeh A, Nikfar S, Farshchi A, Ghiasi G, Abdollahi M. Patterns of antibiotic consumption in Iran during 2000-2009. Int J Antimicrob Agents 2011; 37: 489-90.
5. Kebriaeezadeh A, Abdollahi M. Iran seeks to boost domestic pharma production. Scrip 2002; 2695: 16.
6. Using indicators to measure country pharmaceutical situations, Fact Book on WHO Level I and Level II monitoring indicators, World Health Organization, 2006.
7. The world medicines situation, World Health Organization, 2004.
8. White F, Nanan D. Community health case studies selected from developing and developed countries-common principles for moving from evidence to action. Arch Med Sci 2008; 4: 358-63.
9. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4: 348-61. (Pubitemid 32946233)
10. Davis P, Lay-Yee R, Pearson J. Using micro-simulation to create a synthesised data set and test policy options: the case of health service effects under demographic ageing. Health Policy 2010; 97: 267-74.
11. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems - the mathematical formulation. Biomed Inform 2002; 35: 37-50. (Pubitemid 35216430)
12. Mullahy J. Econometric modeling of health care costs and expenditures a survey of analytical issues and related policy considerations. Med Care 2009; 47 (7 Suppl 1): S104-8.
13. DiRusso SM, Sullivan T, Holly C, Cuff SN, Savino J. An artificial neural network as a model for prediction of survival in trauma patients: validation for a regional trauma area. J Trauma 2000; 49: 212-20.
14. Galea S, Hall C, Kaplan GA. Social epidemiology and complex system dynamic modelling as applied to health behaviour and drug use research. Int J Drug Policy 2009; 20: 209-16.
15. McDonnell G, Heffernan M, Faulkner A. Using system dynamics to analyse health system performance within the WHO framework in international system dynamics Pty Ltd, 2005.